Novartis patent for oral form of top-selling MS drug obvious, IP Australia says
Intellectual Property May 13, 2019 12:31 pm By Miklos Bolza | Sydney

A proposed Novartis patent for an oral form of its top-selling multiple sclerosis drug Gilenya is invalid for lack of inventive step, IP Australia has […]

Subscribe for instant access to all Lawyerly content. Already a subscriber? Login here. Want to test drive Lawyerly? Contact us to take a free trial.